Navigation Links
China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent

BEIJING, April 3, 2008 /Xinhua-PRNewswire-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapy systems, today announced the completion of development of the Prostate Cancer FISH Detection Kit (the "Kit"), a prostate cancer-specific molecular diagnostic test based on the Fluorescent in situ Hybridization ("FISH") technology. The Company expects to launch the Kit in July 2008.

The Kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues. Dysregulation of ETS family members through fusions with TMPRSS2 are implicated as cancer-causing gene rearrangements in prostate cancer, which can aid in the detection of early prostate cancer. The Kit consists of three dual-color probe sets, namely TMPRSS2/ETV1 probes, TMPRSS2/ERG probes and TMPRSS2/ETV4 probes. Studies have shown that TMPRSS2/ETS gene fusions occur in approximately 80 percent of prostate cancer cases, indicating that the application of TMPRSS2/ETS gene fusions as specific biomarkers can significantly increase the sensitivity for prostate cancer diagnosis. In addition, it has been reported that the TMPRSS2/ERG fusion may have prognostic significance.

"The successful development of the Kit is a milestone in expanding our FISH reagent portfolio, which represents the first significant product developed by our researchers since the FISH acquisition in 2007," said Mr. Xiaodong Wu, Chairman and CEO of the Company. "Our FISH business has become an important growth driver of the Company and we believe the continual launch of new FISH reagents with huge potential of diagnostic application will drive the growth of our recurring reagent business rapidly."

Prostate cancer is one of the most frequent cancers among men in China and many other countries. In China, prostate-related diseases affect about 60-70% of men over 60 years of age of which the population is about 80 million. Among them, patients with prostate enlargement who need surgical therapy have the opportunity to benefit from the use of the Kit to resolve the diagnosis of prostate cancer.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products using Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situ Hybridization (FISH) technology, to detect and monitor various diseases and disorders, and products using High Intensity Focused Ultrasound (HIFU) for the treatment of solid cancers and benign tumors. For more information, please visit .

For more information, please contact:

China Medical Technologies, Inc.

Sam Tsang

Tel: +86-10-6530-8833


SOURCE China Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results
2. China Shenghuo Pharmaceutical Holdings, Inc. to Present at Brean Murray Carret & Co. Mainland China Investor Tour
3. China Nepstar Chain Drugstore to Accept TransCard at Shenzhen Outlets
4. China Bionanometer Industries (CBIU) Describes their Current Production Capacity and Product Lines
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. China Shenghuo Reports Full Year 2007 Financial Results
7. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
8. China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour
9. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
10. China Yingxia International Announces Soybean Milk Production Lines Acquisition
11. Cells from the Research Institute of the MUHC on the road to China
Post Your Comments:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: